The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser

Last updated: May 15, 2023
Sponsor: Xijing Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

Inflammatory Comedones

Rash

Acne

Treatment

Fractional CO2 laser

Dezocine

Clinical Study ID

NCT05861063
XijingH-PF-20232019-F-1
  • Ages 18-60
  • All Genders

Study Summary

The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age: 18-60 years old, regardless of gender;
  2. Clinical diagnosis of atrophic acne scars;
  3. Planning to undergo ultra-pulsed CO2 lattice laser therapy;
  4. The patient agrees to participate in this experiment and signs an informed consentform

Exclusion

Exclusion Criteria: 1. Those who take sedative drugs for a long time; 2. Patients with sleep apnea syndrome, previous history of hypertension, and bloodpressure greater than 160/100mmHg 3. People with severe heart and lung diseases, liver and kidney diseases, psychosis,pregnancy, and communication disorders; 4. Persons who are known to be allergic to the main drug or any of the excipients inDezocine injection; 5. Increased intracranial pressure or head injury; 6. Acute and chronic alcoholism; 7. People with hypotension, hypothyroidism, acute episodes of asthma, and epilepsy

Study Design

Total Participants: 105
Treatment Group(s): 2
Primary Treatment: Fractional CO2 laser
Phase: 4
Study Start date:
February 11, 2023
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Dermatology Derpartment of Xijing Hospital

    Xi'an, Shaanxi 710032
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.